CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
The company also announced the launch of its IQLung Treatment Guidance Testing Strategy. It includes the GeneStrat NGS and provides a broader view of a patient’s disease state. The testing strategy also includes blood-based proteomic and genomic testing workflows for early- and advanced-stage lung cancer that can aid physicians in making treatment decisions. Biodesix plans to add tests, which are in development, to the IQLung portfolio.
Biodesix, 303-417-0500
Pages: 1 2